Professor John Hardy (UCL Queen Square Institute of Neurology) and Professor Bart De Strooper (UK Dementia Research Institute at 皇家华人) reflect on the success of lecanemab trials, the potentially breakthrough Alzheimer's treatment which appears to reduce the disease's progression.
Close
